Utz Brands news

Under investigation for potential breach of fiduciary duties regarding fair process and fair value in proposed $14.25/share acquisition

The company is under investigation for potential breaches of fiduciary duty in its merger transaction. The deal structure appears to favor controlling shareholders (Rice and Lissette families) over public shareholders, who cannot participate in the post-merger equity ownership despite being asked to approve the transaction. The $14.25 per share offer is being questioned as potentially undervalued.

Company is under investigation for potential securities law violations and fiduciary duty breaches related to its acquisition, raising concerns about fair dealing for shareholders.

Company is under investigation for potential securities law violations and breach of fiduciary duties related to its $14.25 per share sale, with concerns about fair dealing and insider benefits.

Stock surged 88.72% on announcement of $2.9 billion take-private deal at $14.25 per share, representing a 91% premium over previous close. Recent improvements in adjusted free cash flow and positive guidance also support positive sentiment.

Zacks Rank #2 with modest growth outlook: 3.7% sales growth expected but 2.4% earnings decline projected. Minimal earnings surprise of 1.8% suggests stable but unspectacular performance.

Holds a Zacks Rank #2 (Buy) with modest sales growth of 3.7% expected, but EPS is projected to decline 2.4% year-over-year with only a 1.8% average earnings surprise.

Mentioned as a comparable company with Zacks Rank #2 (Buy), showing modest consensus estimate for 3.7% sales growth and a trailing four-quarter earnings surprise of only 1.8%.

Rated Zacks Rank #2 (Buy) with modest 3.7% projected sales growth and low trailing four-quarter earnings surprise average of 1.8%, indicating stable but unspectacular performance.

Zacks Rank #2 (Buy) with modest 3.7% sales growth expected, but EPS expected to decline 2.4% year-over-year with only 1.8% average earnings surprise

Rated Zacks Rank #2 (Buy) with modest sales growth of 3.7% expected, but EPS is projected to decline 2.4%. Trailing four-quarter earnings surprise of only 1.8% suggests limited upside surprises.

UTZ carries a Zacks Rank #2 with modest sales growth of 3.7% but projected earnings decline of 2.4%. The company's minimal 1.8% average trailing four-quarter earnings surprise indicates limited upside surprises and modest growth prospects.

Mentioned as a comparable consumer staples stock with a Zacks Rank #2, but has no connection to the collagen business strategy discussed in the main article.

Zacks Rank #2 (Buy) but mixed fundamentals: modest 3.7% projected sales growth with consensus EPS declining 2.4% year-over-year. Low trailing four-quarter earnings surprise of 1.8% indicates limited upside momentum.

Zacks Rank #2 (Buy) but with modest growth expectations (3.7% sales, -2.4% earnings decline) and minimal earnings surprises (1.8%), indicating stable but uninspiring performance.

Carries Zacks Rank #2 (Buy) with modest sales growth estimate of 3.7% and minimal trailing four-quarter earnings surprise average of 1.8%.

Legitimate national salty snack brand with portfolio rationalization efforts. Snacks are durable consumer category with strong brand loyalty constraining private-label competition.